Genetic variants of sex hormone receptors in patients with atrial fibrillation

Genetic variants of sex hormone receptors in patients with atrial fibrillation - GENE-AF

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033526

Enrollment

Registered

2024-01-31

Start date

2024-01-24

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I48

Interventions

Group 1: The study includes testing for genetic variants in the GPER1 gene and in other sex hormone receptor genes in patients with atrial fibrillation. In addition, an analysis of the genes associate

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients with atrial fibrillation (ICD-10 code: I48.0 or I48.1) > 18 years of age - Postmenopausal status in women (last menstrual period > 12 months ago). Premenopausal women would experience excessive hormonal fluctuations due to their menstrual cycle. - Ability to give consent and sufficient knowledge of German

Exclusion criteria

Exclusion criteria: - Obesity = size II (BMI = 35kg/m2) - Manifest hyperthyroidism (TSH 15 mg/dl) - Indications of CHD (corresponding symptoms, echocardiographic or ECG morphological abnormalities) or already diagnosed CHD - Hypokalemia (K+ < 3.0 mmol/l) - Acute or chronic right heart strain (systolic pulmonary artery pressure (sPAP) = 36 mmHg in transthoracic echocardiography) (e.g. pulmonary artery embolism or COPD) - Obstructive sleep apnea syndrome (OSAS) - Chronic renal insufficiency - (uncontrolled) arterial hypertension - (Z.n.) malignant gynecological tumor disease, (Z.n.) prostate carcinoma, (Z.n.) hormonally active tumors - Z.n. ovariectomy or Z.n. orchiectomy - Hormone metabolism disorders with an influence on sex hormone levels - Daily intake of NSAIDs (diclofenac, ASA, naproxen or ibuprofen), - Intake of opiates or cortisone compounds - Hormonal therapy - Non-consenting ability

Design outcomes

Primary

Measure	Time frame
- Prevalence of genetic variants in sex hormone receptor genes and associated proteins in patients with atrial fibrillation and gender differences of these variants - Prevalence of altered cellular signal transduction by sex hormone receptor variants in patients with atrial fibrillation	—

Secondary

Measure	Time frame
Sex hormone levels in patients with atrial fibrillation compared to patients without atrial fibrillation	—

Countries

Germany

Contacts

Public ContactSophia Schulze Lammers

Klinikum Bielefeld Mitte

sophiacaroline.schulzelammers@klinikumbielefeld.de00495215813401

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026